48.62 USD
+0.36 (+0.75%)
48.92 USD
+0.3 (+0.62%)
Taking everything into account, SNY scores 6 out of 10 in our fundamental rating. SNY was compared to 191 industry peers in the Pharmaceuticals industry. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. SNY may be a bit undervalued, certainly considering the very reasonable score on growth Finally SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
In the past year SNY had a positive cash flow from operations.
In the past 5 years SNY has always been profitable.
Each year in the past 5 years SNY had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 11.05%, SNY belongs to the best of the industry, outperforming 92.15% of the companies in the same industry.
With an excellent Return On Equity value of 19.73%, SNY belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 13.84%, SNY belongs to the top of the industry, outperforming 93.19% of the companies in the same industry.
SNY had an Average Return On Invested Capital over the past 3 years of 7.31%. This is significantly below the industry average of 12.85%.
The 3 year average ROIC (7.31%) for SNY is below the current ROIC(13.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
The Profit Margin of SNY (20.35%) is better than 91.10% of its industry peers.
SNY's Profit Margin has improved in the last couple of years.
SNY has a Operating Margin of 23.59%. This is amongst the best in the industry. SNY outperforms 90.58% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 71.70%, SNY is doing good in the industry, outperforming 78.53% of the companies in the same industry.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SNY is creating value.
Compared to 1 year ago, SNY has about the same amount of shares outstanding.
SNY has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for SNY has been reduced compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of SNY is 2.21, which is a good value as it means it would take SNY, 2.21 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.21, SNY belongs to the best of the industry, outperforming 93.19% of the companies in the same industry.
SNY has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
SNY has a Debt to Equity ratio (0.21) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.88
WACC7.36%
2.3 Liquidity
A Current Ratio of 1.27 indicates that SNY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.27, SNY is doing worse than 76.44% of the companies in the same industry.
A Quick Ratio of 0.94 indicates that SNY may have some problems paying its short term obligations.
SNY has a Quick ratio of 0.94. This is in the lower half of the industry: SNY underperforms 78.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -5.35% in the last year.
SNY shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.10% yearly.
Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 2.56% in the last year.
The Revenue has been growing slightly by 3.31% on average over the past years.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
Based on estimates for the next years, SNY will show a small growth in Earnings Per Share. The EPS will grow by 7.11% on average per year.
The Revenue is expected to grow by 4.55% on average over the next years.
EPS Next Y3.02%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
EPS Next 5Y7.11%
Revenue Next Year0.64%
Revenue Next 2Y3.51%
Revenue Next 3Y4.42%
Revenue Next 5Y4.55%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.98, which indicates a very decent valuation of SNY.
Compared to the rest of the industry, the Price/Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 90.58% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of SNY to the average of the S&P500 Index (26.59), we can say SNY is valued rather cheaply.
With a Price/Forward Earnings ratio of 9.70, the valuation of SNY can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 87.96% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.80. SNY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.98 | ||
| Fwd PE | 9.7 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNY is valued cheaply inside the industry as 97.38% of the companies are valued more expensively.
91.10% of the companies in the same industry are more expensive than SNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.08 | ||
| EV/EBITDA | 5.49 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)3.64
PEG (5Y)2.15
EPS Next 2Y5.77%
EPS Next 3Y5.98%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 4.64%, which is a nice return.
Compared to an average industry Dividend Yield of 6.46, SNY pays a better dividend. On top of this SNY pays more dividend than 97.38% of the companies listed in the same industry.
SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.64% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
SNY has decreased its dividend in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
SNY pays out 34.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
48.62
+0.36 (+0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.31%
Inst Owner Change-5.34%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap118.10B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Analysts81.38
Price Target62.23 (27.99%)
Short Float %0.28%
Short Ratio1.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.64% |
Yearly Dividend2.21
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)-0.08%
PT rev (3m)-2.34%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-4.38%
EPS NY rev (1m)0.24%
EPS NY rev (3m)-1.11%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-1.69%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.98 | ||
| Fwd PE | 9.7 | ||
| P/S | 1.5 | ||
| P/FCF | 10.08 | ||
| P/OCF | 8.92 | ||
| P/B | 1.45 | ||
| P/tB | 10.92 | ||
| EV/EBITDA | 5.49 |
EPS(TTM)4.43
EY9.11%
EPS(NY)5.01
Fwd EY10.31%
FCF(TTM)4.82
FCFY9.92%
OCF(TTM)5.45
OCFY11.21%
SpS32.52
BVpS33.53
TBVpS4.45
PEG (NY)3.64
PEG (5Y)2.15
Graham Number57.81
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.36%
ROIC/WACC1.88
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y3.02%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
EPS Next 5Y7.11%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year0.64%
Revenue Next 2Y3.51%
Revenue Next 3Y4.42%
Revenue Next 5Y4.55%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year29.46%
EBIT Next 3Y13.42%
EBIT Next 5Y11.66%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI-ADR / SNY FAQ
What is the fundamental rating for SNY stock?
ChartMill assigns a fundamental rating of 6 / 10 to SNY.
What is the valuation status for SNY stock?
ChartMill assigns a valuation rating of 8 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.
How profitable is SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
What is the valuation of SANOFI-ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 10.98 and the Price/Book (PB) ratio is 1.45.
Can you provide the financial health for SNY stock?
The financial health rating of SANOFI-ADR (SNY) is 4 / 10.